CN104244944B - 用于治疗脊髓性肌萎缩症的化合物 - Google Patents
用于治疗脊髓性肌萎缩症的化合物 Download PDFInfo
- Publication number
- CN104244944B CN104244944B CN201280071056.5A CN201280071056A CN104244944B CN 104244944 B CN104244944 B CN 104244944B CN 201280071056 A CN201280071056 A CN 201280071056A CN 104244944 B CN104244944 B CN 104244944B
- Authority
- CN
- China
- Prior art keywords
- bases
- chromen
- ones
- pyrazine
- yls
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CCC(CC1)C2C(CC)*C=CC(C)CCCC1C2 Chemical compound CCC(CC1)C2C(CC)*C=CC(C)CCCC1C2 0.000 description 17
- VJOUHFZHEUCANO-UHFFFAOYSA-N BCC(C1=CC(C=CC(C2)F)=C2OC1=O)=O Chemical compound BCC(C1=CC(C=CC(C2)F)=C2OC1=O)=O VJOUHFZHEUCANO-UHFFFAOYSA-N 0.000 description 1
- LSCHAZFMFBUCOV-CTZVLDLTSA-N CC(CC/C=C\C(N1CCNCC1)=C)N1N=C(C)SC1=N Chemical compound CC(CC/C=C\C(N1CCNCC1)=C)N1N=C(C)SC1=N LSCHAZFMFBUCOV-CTZVLDLTSA-N 0.000 description 1
- CERDICCHQPCUDZ-HWZXHQHMSA-N CC([C@](C)(C(CBr)=O)C(O)=O)F Chemical compound CC([C@](C)(C(CBr)=O)C(O)=O)F CERDICCHQPCUDZ-HWZXHQHMSA-N 0.000 description 1
- GLULNELZDJIROH-UHFFFAOYSA-N CC1=CN2C=C(C3=Cc4ccc(CN(C)CCO)cc4O/C3=[O]/C)NC2CC=C1 Chemical compound CC1=CN2C=C(C3=Cc4ccc(CN(C)CCO)cc4O/C3=[O]/C)NC2CC=C1 GLULNELZDJIROH-UHFFFAOYSA-N 0.000 description 1
- WPUZGDHERSSZGI-UHFFFAOYSA-N CC1C(C)=CN(C=C(C=C2)C3=Cc(ccc(CCCN(C)C)c4)c4OC3=O)C2=CC1 Chemical compound CC1C(C)=CN(C=C(C=C2)C3=Cc(ccc(CCCN(C)C)c4)c4OC3=O)C2=CC1 WPUZGDHERSSZGI-UHFFFAOYSA-N 0.000 description 1
- IUTIUNXOYCHQDT-UHFFFAOYSA-N CCC(C1)=CC=CC2=C1OCC(C(C=C)/N=C1\NC=C=C(C)CC=C1)=C2 Chemical compound CCC(C1)=CC=CC2=C1OCC(C(C=C)/N=C1\NC=C=C(C)CC=C1)=C2 IUTIUNXOYCHQDT-UHFFFAOYSA-N 0.000 description 1
- VCBBNHMMWJMKSQ-UHFFFAOYSA-N CCCNCCNc1ccc(C=C(c(cc2)n[n]2-c2ccccc2)C(O2)=O)c2c1 Chemical compound CCCNCCNc1ccc(C=C(c(cc2)n[n]2-c2ccccc2)C(O2)=O)c2c1 VCBBNHMMWJMKSQ-UHFFFAOYSA-N 0.000 description 1
- VYMJUZXFYAREJY-UHFFFAOYSA-N CCOC(Cc1nc(cccc2)c2[s]1)=O Chemical compound CCOC(Cc1nc(cccc2)c2[s]1)=O VYMJUZXFYAREJY-UHFFFAOYSA-N 0.000 description 1
- FXHRAKUEZPSMLJ-UHFFFAOYSA-N CN1CCNCCC1 Chemical compound CN1CCNCCC1 FXHRAKUEZPSMLJ-UHFFFAOYSA-N 0.000 description 1
- BSZKLVSTNGEDHN-UHFFFAOYSA-N Cc([s]1)n[n]2c1nc(C(C(Oc1c3)=O)=Cc1ccc3F)c2 Chemical compound Cc([s]1)n[n]2c1nc(C(C(Oc1c3)=O)=Cc1ccc3F)c2 BSZKLVSTNGEDHN-UHFFFAOYSA-N 0.000 description 1
- HMPUHXCGUHDVBI-UHFFFAOYSA-N Cc1nnc(N)[s]1 Chemical compound Cc1nnc(N)[s]1 HMPUHXCGUHDVBI-UHFFFAOYSA-N 0.000 description 1
- RAIPHJJURHTUIC-UHFFFAOYSA-N Nc1ncc[s]1 Chemical compound Nc1ncc[s]1 RAIPHJJURHTUIC-UHFFFAOYSA-N 0.000 description 1
- JJHPPFYPLSFKPO-UHFFFAOYSA-N OCC#Cc1ccc(C=CC(O2)=O)c2c1 Chemical compound OCC#Cc1ccc(C=CC(O2)=O)c2c1 JJHPPFYPLSFKPO-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
- C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
- C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
- C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
- C07D311/18—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted otherwise than in position 3 or 7
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pyrane Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161582064P | 2011-12-30 | 2011-12-30 | |
| US61/582,064 | 2011-12-30 | ||
| PCT/US2012/071899 WO2013101974A1 (en) | 2011-12-30 | 2012-12-28 | Compounds for treating spinal muscular atrophy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104244944A CN104244944A (zh) | 2014-12-24 |
| CN104244944B true CN104244944B (zh) | 2018-06-08 |
Family
ID=48698624
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201280071056.5A Active CN104244944B (zh) | 2011-12-30 | 2012-12-28 | 用于治疗脊髓性肌萎缩症的化合物 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | USRE47689E1 (enExample) |
| EP (1) | EP2797592B1 (enExample) |
| JP (1) | JP6193881B2 (enExample) |
| KR (1) | KR102057351B1 (enExample) |
| CN (1) | CN104244944B (enExample) |
| BR (1) | BR112014016287B1 (enExample) |
| CA (1) | CA2861609C (enExample) |
| EA (1) | EA029984B1 (enExample) |
| MX (1) | MX352861B (enExample) |
| WO (1) | WO2013101974A1 (enExample) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2733644T3 (es) | 2012-01-26 | 2019-12-02 | Ptc Therapeutics Inc | Compuestos para tratar atrofia muscular espinal |
| JP6092897B2 (ja) | 2012-02-10 | 2017-03-08 | ピーティーシー セラピューティクス， インコーポレイテッド | 脊髄性筋萎縮症を治療するための化合物 |
| EA029155B1 (ru) | 2012-03-01 | 2018-02-28 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Соединения для лечения спинальной мышечной атрофии |
| CA2868026C (en) | 2012-03-23 | 2021-02-16 | Ptc Therapeutics, Inc. | Compounds for treating spinal muscular atrophy |
| MX2015008146A (es) * | 2012-12-24 | 2016-01-20 | Univ Ramot | Agentes para tratar enfermedades geneticas derivadas de mutaciones sin sentido y metodos para identificarlas. |
| CN103360269B (zh) * | 2013-07-16 | 2015-07-08 | 临海市联盛化学有限公司 | 一种3-氯-2-氨基苯酚的制备方法 |
| CN105392790B (zh) | 2013-08-19 | 2019-04-19 | 豪夫迈·罗氏有限公司 | 4H-吡啶并[1,2-a]嘧啶-4-酮化合物制备用于预防或治疗癌症的药物的用途 |
| EP3082820B1 (en) | 2013-12-19 | 2022-07-20 | PTC Therapeutics, Inc. | Methods for modulating the amount of rna transcripts |
| WO2015095449A1 (en) * | 2013-12-19 | 2015-06-25 | Ptc Therapeutics, Inc. | Methods for modulating the amount rna transcripts |
| EP3134388B1 (en) | 2014-04-22 | 2019-01-09 | Universität Basel | Novel manufacturing process for triazine, pyrimidine and pyridine derivatives |
| US10882868B2 (en) | 2014-05-15 | 2021-01-05 | Hoffmann-La Roche Inc. | Compounds for treating spinal muscular atrophy |
| DK3143025T3 (da) * | 2014-05-15 | 2019-12-09 | Hoffmann La Roche | Forbindelser til behandling af spinal muskelatrofi |
| CA2952895C (en) * | 2014-06-25 | 2023-09-26 | F. Hoffmann-La Roche Ag | Imidazo[1,2-a]pyrazin-1yl-benzamide compounds for treating spinal muscular atrophy |
| CN104803921A (zh) * | 2015-03-14 | 2015-07-29 | 长沙深橙生物科技有限公司 | 一种苯取代嘧啶衍生物的制备方法 |
| CN104744376A (zh) * | 2015-03-14 | 2015-07-01 | 长沙深橙生物科技有限公司 | 一种2-异丙基嘧啶衍生物的制备方法 |
| EP4249472A3 (en) | 2015-05-30 | 2023-12-13 | PTC Therapeutics, Inc. | Methods for modulating rna splicing |
| JP2018533594A (ja) * | 2015-11-12 | 2018-11-15 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 筋萎縮性側索硬化症を処置するための化合物 |
| JP6659841B2 (ja) | 2015-11-12 | 2020-03-04 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 脊髄性筋萎縮症を処置するための組成物 |
| WO2017087364A1 (en) * | 2015-11-16 | 2017-05-26 | Ptc Therapeutics, Inc. | Hydrogen isotope-enriched analogues of 1,2,4-oxandiazole benzoic acid compounds, compositions and uses thereof |
| CN110946865B (zh) | 2015-12-10 | 2024-01-26 | Ptc医疗公司 | 用于治疗亨廷顿病的方法 |
| EP3386978B1 (en) | 2015-12-10 | 2021-01-27 | H. Hoffnabb-La Roche Ag | Bridged piperidine derivatives |
| BR112018017077A2 (pt) * | 2016-02-23 | 2018-12-26 | Univ Indiana Res & Tech Corp | terapias de combinação para tratamento de atrofia muscular espinhal |
| US10906905B2 (en) | 2016-10-14 | 2021-02-02 | Jiangsu Hengrui Medicine Co., Ltd. | Five-membered heteroaryl ring bridged ring derivative, preparation method therefor and medical use thereof |
| WO2018098446A1 (en) | 2016-11-28 | 2018-05-31 | Ptc Therapeutics, Inc | Methods for modulating rna splicing |
| EP3634953B1 (en) | 2017-06-05 | 2024-01-03 | PTC Therapeutics, Inc. | Compounds for treating huntington's disease |
| BR112019026508A2 (pt) | 2017-06-14 | 2020-07-14 | Ptc Therapeutics, Inc. | métodos para modificar o splicing do rna |
| MX2019015578A (es) | 2017-06-28 | 2020-07-28 | Ptc Therapeutics Inc | Metodos para tratar la enfermedad de huntington. |
| CN111163838B (zh) | 2017-06-28 | 2023-03-28 | Ptc医疗公司 | 用于治疗亨廷顿氏病的方法 |
| RU2020105929A (ru) | 2017-08-04 | 2021-09-06 | Скайхоук Терапьютикс, Инк. | Способы и композиции для модулирования сплайсинга |
| SG11202002610TA (en) | 2017-09-22 | 2020-04-29 | Hoffmann La Roche | Process for the prepration of 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one derivatives |
| KR20200143376A (ko) | 2018-03-13 | 2020-12-23 | 샤이어 휴먼 지네틱 테라피즈 인크. | 혈장 칼리크레인 억제제로서의 치환된 이미다조피리딘 및 이의 용도 |
| JP7399870B2 (ja) | 2018-03-27 | 2023-12-18 | ピーティーシー セラピューティクス， インコーポレイテッド | ハンチントン病を処置するための化合物 |
| EP3814360B8 (en) | 2018-06-27 | 2024-11-06 | PTC Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| PL3814357T3 (pl) | 2018-06-27 | 2024-09-16 | Ptc Therapeutics, Inc. | Związki heterocykliczne i heteroarylowe do leczenia choroby huntingtona |
| CA3105174A1 (en) | 2018-06-27 | 2020-01-02 | Reborna Biosciences, Inc. | Prophylactic or therapeutic agent for spinal muscular atrophy |
| KR20210038845A (ko) | 2018-06-27 | 2021-04-08 | 피티씨 테라퓨틱스, 인크. | 헌팅턴병 치료를 위한 헤테로아릴 화합물 |
| US20220071953A1 (en) * | 2019-01-08 | 2022-03-10 | Texas Tech University System | Small Molecule Analogs Of The Protein E4ORF1 In The Treatment And Prevention Of Metabolic Disorders |
| JP7603592B2 (ja) | 2019-02-05 | 2024-12-20 | スカイホーク・セラピューティクス・インコーポレーテッド | スプライシングを調節するための方法および組成物 |
| EP3920926A4 (en) | 2019-02-05 | 2022-10-19 | Skyhawk Therapeutics, Inc. | Methods and compositions for modulating splicing |
| CN119638696A (zh) | 2019-02-06 | 2025-03-18 | 斯基霍克疗法公司 | 用于调节剪接的方法和组合物 |
| WO2020163544A1 (en) | 2019-02-06 | 2020-08-13 | Skyhawk Therapeutics, Inc. | Methods and compositions for modulating splicing |
| MX2020013384A (es) | 2019-03-01 | 2021-04-28 | Illumina Cambridge Ltd | Compuestos de comarina sustituidos con amina exocíclica y sus usos como etiquetas fluorescentes. |
| CN109943092A (zh) * | 2019-04-09 | 2019-06-28 | 浙江工业大学 | 具有高荧光量子产率的咪唑类香豆素类染料及其合成方法 |
| CN114245794B (zh) | 2019-05-13 | 2024-09-13 | Ptc医疗公司 | 用于治疗亨廷顿氏病的化合物 |
| US11129829B2 (en) | 2019-06-17 | 2021-09-28 | Skyhawk Therapeutics, Inc. | Methods for modulating splicing |
| WO2021055589A1 (en) | 2019-09-18 | 2021-03-25 | Shire Human Genetic Therapies, Inc. | Heteroaryl plasma kallikrein inhibitors |
| ES2987744T3 (es) | 2019-09-18 | 2024-11-18 | Takeda Pharmaceuticals Co | Inhibidores de calicreína plasmática y usos de los mismos |
| CN110862395B (zh) * | 2019-11-13 | 2020-09-29 | 株洲千金药业股份有限公司 | 一种制备他达拉非重要杂质的原料化合物的制备方法 |
| CN114315807B (zh) * | 2022-01-05 | 2023-09-15 | 江南大学 | 一种吡啶鎓盐光引发剂及其制备方法和应用 |
| CN121488042A (zh) * | 2023-06-09 | 2026-02-06 | 豪夫迈·罗氏有限公司 | 诱导型基因表达系统 |
| US12180195B1 (en) | 2023-11-01 | 2024-12-31 | King Faisal University | 6-(6-bromo-2-oxo-2H-chromen-3-yl)-4-(2,4-dichlorophenyl)-2-alkoxynicotinonitrile as an antimicrobial compound |
| WO2025111409A1 (en) * | 2023-11-21 | 2025-05-30 | Biogen Ma Inc. | Heterocyclic compounds of formula (i) for use in the treatment of spinal muscular atrophy via modulation of smn2 splicing |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008074798A1 (en) * | 2006-12-20 | 2008-06-26 | Neurosearch A/S | Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| WO2009098209A1 (en) * | 2008-02-05 | 2009-08-13 | Neurosearch A/S | Novel 9-aza-bicyclo[3.3.1]non-3-yloxy chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1020636B (de) * | 1954-11-12 | 1957-12-12 | Geigy Ag J R | Verfahren zur Herstellung von 3-Phenyl-7-acylamino-cumarinen |
| CH419146A (de) * | 1961-04-27 | 1966-08-31 | Geigy Ag J R | Verfahren zur Herstellung von 3-Phenyl-7-pyrazolyl-cumarinen |
| US3311636A (en) * | 1963-03-14 | 1967-03-28 | Upjohn Co | Organic chemical compounds and process |
| DE1245306B (de) | 1963-05-11 | 1967-07-27 | Bayer Ag | Aufhellungsmittel |
| DE1594845C3 (de) | 1966-03-19 | 1982-05-19 | Bayer Ag, 5090 Leverkusen | Substituierte v-Triazol-(2)-yl-cumarinverbindungen und deren Verwendung als Aufhellungsmittel |
| CH505089A (de) * | 1968-08-23 | 1971-03-31 | Bayer Ag | Verfahren zur Herstellung von 3-substituierten-7-Aminocumarinen |
| JPS5023687B2 (enExample) * | 1972-03-07 | 1975-08-09 | ||
| CH620322B (de) * | 1976-03-26 | Ciba Geigy Ag | Verwendung von 3-phenyl-7-(v-triazol-2-yl)-cumarinen zum optischen aufhellen von organischen materialien. | |
| FR2361680A1 (fr) * | 1976-08-11 | 1978-03-10 | Du Pont | Plaques d'impression planographiques et leur preparation |
| DE2807761A1 (de) | 1978-02-23 | 1979-08-30 | Basf Ag | Cumarinderivate |
| DE2815956A1 (de) * | 1978-04-13 | 1979-10-18 | Bayer Ag | Verfahren zur herstellung von in 2-stellung substituierten triazolen-1,2,3 |
| DE2950291A1 (de) * | 1979-12-14 | 1981-06-19 | Basf Ag, 6700 Ludwigshafen | Neue cumarinverbindungen und verfahren zur herstellung von cumarinverbindungen |
| JPS56140990A (en) * | 1980-04-07 | 1981-11-04 | Showa Kagaku Kogyo Kk | 3-phenylcoumarin derivative bearing dicarbonylimide group |
| DE3101141A1 (de) | 1981-01-16 | 1982-09-02 | Bayer Ag, 5090 Leverkusen | Triazolylcumarinverbindungen, sowie deren herstellung und verwendung als optiche aufheller, scintillatoren und laserfarbstoffe |
| JPS62267285A (ja) | 1986-05-16 | 1987-11-19 | Kyorin Pharmaceut Co Ltd | 新規ピラゾロピリジン誘導体 |
| EP0428939B1 (de) * | 1989-11-21 | 1996-01-17 | Bayer Ag | Cumarinderivate, Verfahren zu ihrer Herstellung, ihre Verwendung und Thiazolyl-essigsäurederivate als Zwischenprodukte |
| EP0429907B1 (de) | 1989-11-21 | 1994-06-01 | Bayer Ag | Optischer Biosensor |
| EP0448241A3 (en) * | 1990-02-28 | 1992-03-04 | Konica Corporation | Light-sensitive silver halide photographic material |
| CA2123740C (en) * | 1993-05-19 | 2002-12-17 | Hee-Gwon Chae | Electric vacuum cleaner |
| JPH073179A (ja) * | 1993-06-15 | 1995-01-06 | Nippon Kayaku Co Ltd | インクジェットプリント用インク組成物及びこれを用いる染色法 |
| KR20040068240A (ko) * | 2001-12-14 | 2004-07-30 | 노보 노르디스크 에이/에스 | 호르몬 민감성 리파아제의 활성을 감소시키기 위한 화합물및 그들의 사용 |
| GB0205281D0 (en) * | 2002-03-06 | 2002-04-17 | Novartis Ag | Organic compounds |
| CN1180016C (zh) * | 2002-04-04 | 2004-12-15 | 中国石化上海石油化工股份有限公司 | 用于制造增白聚丙烯纤维的增白聚丙烯母粒 |
| EP1550657A4 (en) * | 2002-09-11 | 2009-12-30 | Kureha Corp | AMINO COMPOUNDS AND THEIR USE |
| WO2006078834A1 (en) | 2005-01-21 | 2006-07-27 | Janssen Pharmaceutica N.V. | Novel heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors |
| AR059339A1 (es) | 2006-02-09 | 2008-03-26 | Chugai Pharmaceutical Co Ltd | Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene |
| US8337941B2 (en) * | 2006-07-27 | 2012-12-25 | The Trustees Of Columbia University In The City Of New York | Fluorescent substrates for monoamine transporters as optical false neurotransmitters |
| DE102008018132A1 (de) * | 2008-04-09 | 2009-10-15 | Henkel Ag & Co. Kgaa | Kationische Direktzieher und Mittel zum Färben von keratinhaltigen Fasern |
| US8633019B2 (en) | 2008-05-27 | 2014-01-21 | Ptc Therapeutics, Inc. | Methods for treating spinal muscular atrophy |
| WO2010019243A1 (en) | 2008-08-13 | 2010-02-18 | Ptc Therapeutics, Inc. | Methods for treating viral infections |
| WO2010049044A1 (de) * | 2008-10-29 | 2010-05-06 | Merck Patent Gmbh | Flüssigkristallanzeige |
| ES2733644T3 (es) | 2012-01-26 | 2019-12-02 | Ptc Therapeutics Inc | Compuestos para tratar atrofia muscular espinal |
| JP6092897B2 (ja) | 2012-02-10 | 2017-03-08 | ピーティーシー セラピューティクス， インコーポレイテッド | 脊髄性筋萎縮症を治療するための化合物 |
| EA029155B1 (ru) | 2012-03-01 | 2018-02-28 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Соединения для лечения спинальной мышечной атрофии |
| CA2868026C (en) | 2012-03-23 | 2021-02-16 | Ptc Therapeutics, Inc. | Compounds for treating spinal muscular atrophy |
-
2012
- 2012-12-28 US US15/695,299 patent/USRE47689E1/en active Active
- 2012-12-28 CN CN201280071056.5A patent/CN104244944B/zh active Active
- 2012-12-28 US US14/369,294 patent/US9617268B2/en not_active Ceased
- 2012-12-28 EP EP12862080.4A patent/EP2797592B1/en active Active
- 2012-12-28 WO PCT/US2012/071899 patent/WO2013101974A1/en not_active Ceased
- 2012-12-28 BR BR112014016287-5A patent/BR112014016287B1/pt active IP Right Grant
- 2012-12-28 EA EA201491296A patent/EA029984B1/ru not_active IP Right Cessation
- 2012-12-28 MX MX2014007877A patent/MX352861B/es active IP Right Grant
- 2012-12-28 KR KR1020147021262A patent/KR102057351B1/ko active Active
- 2012-12-28 CA CA2861609A patent/CA2861609C/en active Active
- 2012-12-28 JP JP2014550478A patent/JP6193881B2/ja active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008074798A1 (en) * | 2006-12-20 | 2008-06-26 | Neurosearch A/S | Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| WO2009098209A1 (en) * | 2008-02-05 | 2009-08-13 | Neurosearch A/S | Novel 9-aza-bicyclo[3.3.1]non-3-yloxy chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
Non-Patent Citations (1)
| Title |
|---|
| Vipirinin, a Coumarin-based HIV-1 Vpr Inhibitor, Interacts with a Hydrophobic Region of VPR;Eugene Boon Beng Ong等;《THE JOURNAL OF BIOLOGICAL CHEMISTRY》;20110422;第286卷(第16期);第14049–14056页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP6193881B2 (ja) | 2017-09-06 |
| CA2861609C (en) | 2021-02-16 |
| CN104244944A (zh) | 2014-12-24 |
| KR20140128310A (ko) | 2014-11-05 |
| JP2015504057A (ja) | 2015-02-05 |
| EA201491296A1 (ru) | 2015-01-30 |
| US20150119380A1 (en) | 2015-04-30 |
| CA2861609A1 (en) | 2013-07-04 |
| KR102057351B1 (ko) | 2019-12-18 |
| WO2013101974A1 (en) | 2013-07-04 |
| EP2797592A4 (en) | 2016-01-13 |
| MX2014007877A (es) | 2015-01-16 |
| USRE47689E1 (en) | 2019-11-05 |
| MX352861B (es) | 2017-12-13 |
| BR112014016287A2 (pt) | 2017-07-04 |
| EP2797592B1 (en) | 2019-08-28 |
| US9617268B2 (en) | 2017-04-11 |
| EA029984B1 (ru) | 2018-06-29 |
| EP2797592A1 (en) | 2014-11-05 |
| BR112014016287B1 (pt) | 2022-08-09 |
| HK1202059A1 (en) | 2015-09-18 |
| WO2013101974A8 (en) | 2019-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104244944B (zh) | 用于治疗脊髓性肌萎缩症的化合物 | |
| CN104349777B (zh) | 用于治疗脊髓性肌萎缩的化合物 | |
| EP2809322B9 (en) | Compounds for treating spinal muscular atrophy | |
| CN104470909B (zh) | 用于治疗脊髓性肌萎缩的化合物 | |
| CN104302181B (zh) | 用于治疗脊髓性肌萎缩的化合物 | |
| HK1202059B (en) | Compounds for treating spinal muscular atrophy | |
| HK1202069B (en) | Compounds for treating spinal muscular atrophy | |
| HK1200056B (en) | Compounds for treating spinal muscular atrophy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |